The suitability of PD-L1 inhibitor therapy depends on several factors, including the type of cancer, the level of PD-L1 expression, and the overall health of the patient. Oncologists often use PD-L1 expression levels as a biomarker to determine which patients are most likely to benefit from checkpoint inhibitors. However, even patients with low or no PD-L1 expression can sometimes respond to these therapies.
